Clinical Study
Dabigatran in Secondary Stroke Prevention: Clinical Experience with 106 Patients
Table 3
Bleeding complications.
| | Patient | Age | Baseline mRS | CHA2DS2-VASc | HAS-BLED | Dabigatran dose | Concomitant antiaggregation therapy | Event | TE (months) | Discontinued yes/no | BT |
| | #3 | 80 | 1 | 6 | 3 | 110 | Yes | UGIB | 10 | Yes | Yes | | #10 | 85 | 3 | 9 | 4 | 110 | Yes | Rectal bleeding | 9 | No | No | | #11 | 90 | 3 | 6 | 4 | 110 | No | Rectal bleeding | 1 | No | No | | #12 | 86 | 2 | 5 | 2 | 110 | No | UGIB | 9 | Yes | Yes | | #12 | 86 | 2 | 5 | 3 | 110 | No | CH** | 9 | Yes | No | | #13 | 63 | 0 | 3 | 1 | 150 | No | Metrorrhagia | 1 | No | No | | #14 | 81 | 2 | 6 | 3 | 110 | No | UGIB | 8 | Yes | Yes | | #15 | 87 | 0 | 5 | 3 | 110 | No | UGIB | 6 | No | No | | #16 | 77 | 3 | 6 | 3 | 110 | No | Hematuria | 1 | No | No | | #17 | 78 | 0 | 3 | 1 | 110 | No | Hematuria | 8 | No | No |
|
|
Administration of prothrombin complex concentrate. mRS: Modified Rankin Scale, TE: time to event, BT: blood transfusion, UGIB: upper gastrointestinal bleeding, and CH: cerebral hemorrhage.
|
